Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2013 09:01 ET | Source: TESARO, Inc.

TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting

A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer A RECIST Response Rate of 50% Was Achieved Across All Dose...
June 03, 2013 07:15 ET | Source: TESARO, Inc.

TESARO, Breast International Group (BIG), and the European Organization for Research and Treatment of Cancer (EORTC) Announce Collaboration for Niraparib Clinical Development in Breast Cancer

CHICAGO and BRUSSELS, Belgium, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, Breast International Group (BIG), a non-profit organization...
June 03, 2013 07:01 ET | Source: TESARO, Inc.

TESARO and the European Network of Gynecological Oncological Trial Groups (ENGOT) Forge Partnership to Develop Niraparib for Ovarian Cancer

CHICAGO, June 3, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and the European Network of Gynecological Oncological Trial Groups (ENGOT), a...
May 28, 2013 16:01 ET | Source: TESARO, Inc.

TESARO to Webcast Investor Briefing at ASCO

WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) invites investors and the general public to listen to a webcast of a presentation by the TESARO management team at an...
May 22, 2013 16:01 ET | Source: TESARO, Inc.

TESARO to Present at the Deutsche Bank 38th Annual 2013 Health Care Conference

WALTHAM, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President, will present at the...
May 16, 2013 08:00 ET | Source: TESARO, Inc.

TESARO Announces Presentation of Niraparib Clinical Data at the 2013 ASCO Annual Meeting

Final Phase 1 Results Demonstrate Activity in Ovarian and Breast Cancer Phase 3 Trial in Ovarian Cancer to Begin Enrolling Patients by Mid-Year Phase 3 Trial in Patients With Breast...
May 09, 2013 09:20 ET | Source: TESARO, Inc.

TESARO Announces Election of Dr. James Armitage to Board of Directors and Results of Annual Stockholder Meeting

WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that James O. Armitage, M.D., F.A.C.P., F.R.C.P., has been...
April 25, 2013 16:01 ET | Source: TESARO, Inc.

Tesaro Announces First-Quarter 2013 Operating Results

Phase 3 Trial of Niraparib in Breast Cancer to be Initiated in the Second Half of 2013 Phase 3 Trial of Niraparib in Ovarian Cancer on Track to Begin Enrolling Mid-2013 Top-Line Results...
April 17, 2013 16:01 ET | Source: TESARO, Inc.

TESARO to Announce First Quarter 2013 Financial Results on April 25, 2013

WALTHAM, Mass., April 17, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its first quarter 2013 financial results on Thursday, April 25, 2013, after the close of the U.S. financial...
March 28, 2013 16:01 ET | Source: TESARO, Inc.

TESARO to Present at the 20th Annual Future Leaders in the Biotech Industry Conference

WALTHAM, Mass., March 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 20th Annual...